Propanc Biopharma, Inc. announced that PRP suppresses the TGF-b pathway and the tumor microenvironment in pancreatic cancer, elucidated by one of the Company's joint researchers, Mrs. Belen Toledo Cutillas MSc, at the laboratory of Professor Macarena Peran, PhD, University of Jaen, Granada, Spain. The experiments were conducted with a well-known small molecule inhibitor of the same pathway, comparing it against the effects of PRP, with results showing an even greater suppression by Propanc's novel cancer therapy. TGF-b is a growth factor molecule involved in cell proliferation, migration and survival, and death that influences tumor growth in advanced forms of cancer.

In addition, Mrs. Cutillas also analyzed the same pathway comparing (i) a pancreatic tumor cell line along with a chemoresistant pancreatic tumor cell line with (ii) the same line treated with PRP. It was observed the TGF-b pathway, which is overexpressed in the chemoresistant cell line, decreased drastically when treated with PRP. Mrs. Cutillas concluded that the results appear to confirm that PRP can suppress not only the tumor microenvironment, but also chemoresistant tumor cells, which also plays a key role in how a malignant tumor grows and spreads.

Further experiments will be conducted by developing a series of immunofluorescence and western blot studies that complement these results with other biomarkers. The Company's novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body's primary defense against cancer.